Spotlight On... UT Southwestern team creates new drug that could aid in vaccine development; GSK seeks to expand FluLaval indication; China FDA clears Sinovac to start producing EV71 vaccine; and more...

Researchers at the University of Texas Southwestern Medical Center have discovered a new drug that could help in vaccine development. It activates the innate immune system in a novel way, UT Southwestern said in a statement. "The drug we made appears safe, and boosts immunity in mice. Therefore, the drug, which is straightforward to synthesize and to couple to antigens that induce an immune response, may prove useful in the generation of vaccines," said Dr. Bruce Beutler, Director of UT Southwestern's Center for the Genetics of Host Defense. More

> GlaxoSmithKline ($GSK) filed a regulatory submission in the U.S. to expand the indication of its FluLaval Quadrivalent vaccine. Release

> The China FDA issued a GMP certificate to Sinovac ($SVA), clearing it to start producing a vaccine for EV71, which causes hand, foot and mouth disease. More

> Mymetics announced it will discontinue its RSV collaborative project in July. Release

And Finally... Drexel University researchers found that 75% of vaccine-related posts on Pinterest are negative toward vaccination. Release

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.